Image For Activity Cover
2021 Consensus Pathway of the Taiwan Society of Cardiology on Novel Therapy for Type 2 Diabetes (JACC: Asia Sept 2021)

Type 2 diabetes is a major threat to human health in the 21st century. More than half a billion people may suffer from this pandemic disease in 2030, leading to a huge burden of cardiovascular complications. Recently, 2 novel antidiabetic agents, glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, reduced cardiovascular complications in a number of randomized control trials. To integrate new information and to achieve a streamlined process for better patient care, a working group was appointed by the Taiwan Society of Cardiology to formulate a stepwise consensus pathway for these therapies to reduce cardiovascular events in patients with type 2 diabetes. This consensus pathway is complementary to clinical guidelines, acting as a reference to improve patient care.

JACC: Asia Editor-in-Chief 
Jian’an Wang, MD, PhD, FACC

CME Editor 
Kenneth A. Ellenbogen, MD

Kenneth A. Ellenbogen, MD

Important Dates

Date of Release: September 21, 2021
Term of Approval/Date of CME/MOC/ECME Expiration: September 20, 2022


Availability: On-Demand
Expires on Sep 20, 2022
Cost: FREE
Credit Offered:
1 CME Credit
1 ABIM-MOC Point
1 ECME Credit
Android App Download IOS App Download Powered By